

ASX Announcement: 30 October 2026 (Melbourne, Australia)

Optiscan Imaging Ltd (ASX: OIL)

APPENDIX 4C

QUARTERLY ACTIVITIES & CASHFLOW REPORT

QUARTER ENDED 30 SEPTEMBER 2026

HIGHLIGHTS

- Optiscan lodged two U.S. FDA 510(k) submissions following Quarter-end, after completing substantial technical, clinical, testing and regulatory work during the Quarter:
 - InForm™ - digital pathology device
 - InVue™ - precision surgery device
- Optiscan signed two Research Agreements with Mayo Clinic and initiated U.S. breast cancer and head and neck cancer studies, each designed to evaluate InVue™ and InForm™ in integrated surgical-pathology workflows.
- InSpecta™ was officially launched in the U.S. veterinary market at the American Veterinary Medical Association (AVMA) Convention in Anaheim, California, following lodgment of the device's U.S. FDA dossier as announced in the March 2026 quarter.
- Optiscan invested \$1.957m in R&D during the Quarter, completing substantial testing, validation and regulatory activities required to support the InForm™ and InVue™ U.S. FDA 510(k) submissions.

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or the '**Company**'), a leader in medical imaging using confocal laser endomicroscopy, is pleased to announce its Appendix 4C Quarterly Cashflow report and business update for the quarter ended 30 September 2026 (the '**Quarter**'). All financial results are in Australian dollars and are unaudited.

CEO COMMENT

Optiscan CEO and Managing Director, Dr Camile Farah, said:

"This has been a defining quarter for Optiscan, and I am incredibly proud of what our team has achieved. The lodgment of the InForm™ and InVue™ U.S. FDA 510(k) submissions shortly after Quarter-end reflects an enormous collective effort across our technical, clinical, quality and regulatory functions.

These submissions are among the most significant milestones in Optiscan’s recent history. They move our lead human-use platforms into formal FDA review and importantly bring us closer to potential entry into the U.S. digital pathology and precision surgery markets.”

“We have also continued to build the clinical and commercial foundations needed to support these products. Our new studies with Mayo Clinic, ongoing Australian clinical programs and launch of InSpecta™ in the U.S. veterinary market are creating valuable evidence, relationships and market experience.

Our focus now is on progressing the FDA review process while continuing to strengthen our clinical reference network, manufacturing readiness and commercial capabilities. There is still important work ahead, but the pieces of our strategy are increasingly coming together, and we are excited about the opportunities before us.”

U.S. FDA 510(K) SUBMISSIONS FOR INFORM™ AND INVUE™

During the Quarter, Optiscan maintained a whole-of-company focus on completing the testing, validation and documentation required to support U.S. Food and Drug Administration (‘**U.S. FDA**’) 510(k) submissions for InForm™ and InVue™. This work brought together technical and clinical evidence, external testing, verification and validation, risk management, quality documentation and comprehensive submission packages for both products.

Following Quarter-end, Optiscan lodged its InForm™ 510(k) submission on 1 October 2026 and its InVue™ 510(k) submission on 5 October 2026, as announced on the respective dates.

U.S. FDA Status	Device	Application
Submitted – Pending review	InForm™	Digital pathology
Submitted – Pending review	InVue™	Precision surgery
Commercially launched	InSpecta™	Veterinary medicine

The U.S. FDA regulatory process is a global benchmark for quality, safety and credibility, requiring detailed evidence and documentation to support product claims. Over the past two years, Optiscan has worked with leading regulatory experts to align its submissions with current U.S. FDA requirements.

Significance of the two U.S. FDA submissions

The lodgement of the InForm™ and InVue™ 510(k) submissions represent significant regulatory, strategic and commercial milestones for Optiscan. The applications move the Company’s flagship human-use devices beyond internal development, testing and validation into formal independent FDA review, supported by substantial technical, performance, clinical, safety, risk-management and quality evidence. Subject to successful review and clearance for their respective indications, the submissions would provide the regulatory foundation for commercial distribution in the U.S. and mark a major transition from product development toward market entry.

Together, InForm™ and InVue™ demonstrate the maturity and versatility of Optiscan's core imaging platform across the complementary fields of digital pathology and precision surgery. InForm™ is designed to deliver real-time, slide-free microscopic imaging of fresh or fixed tissue within pathology workflows either intra-operatively in the operating room or post-operatively in the pathology lab, while InVue™ places cellular-level imaging and visualization capabilities directly in the hands of surgeons while they operate. This complementary positioning supports Optiscan's strategy to develop an integrated surgical-pathology ecosystem with potential applications across multiple tissues, cancer types, procedures and clinical settings.

The submissions also demonstrate Optiscan's ability to execute complex, parallel medical-device development programs and have strengthened its capabilities across regulatory affairs, clinical development, quality systems, engineering, manufacturing and operational execution. These capabilities provide a strong foundation for future regulatory submissions and broader portfolio development.

Commercially, the submissions advance Optiscan toward substantial U.S. surgery and pathology markets with differentiated products that bring cellular-level imaging capabilities closer to the point of clinical decision-making. While FDA review progresses, Optiscan will continue generating clinical evidence, developing reference sites, engaging customers and commercial partners, and advancing manufacturing scale-up and market-entry readiness. This allows its regulatory and commercial programs to progress in parallel.

MAYO CLINIC RESEARCH AGREEMENTS AND U.S. CLINICAL EVIDENCE

During the Quarter, Optiscan expanded its clinical collaboration with Mayo Clinic in Rochester, Minnesota through two Research Agreements covering breast cancer and head and neck cancer imaging studies. The studies are designed to evaluate InVue™ for in vivo surgical imaging and InForm™ for ex vivo digital pathology imaging within integrated clinical workflows, while generating data from U.S. patient populations.

These studies are strategically aligned with the InVue™ and InForm™ 510(k) submissions. Although both applications have now been lodged, the programs will continue to expand the clinical evidence base, support responses to the FDA when further information is requested, refine workflow integration and build the clinical reference network needed for future adoption and commercialisation.

Mayo Clinic breast imaging study

The breast imaging study will evaluate InVue™ and InForm™ in 35 U.S. patients undergoing breast-conserving surgery. InVue™ will be used to capture in vivo microscopic images of the surgical cavity following tumour resection, while InForm™ will be used to assess excised tissue ex vivo. The study is designed to evaluate intraoperative tissue assessment and validate an integrated surgical-pathology workflow.

The collaboration combines Mayo Clinic's surgical, pathology and patient-care expertise with Optiscan's imaging platforms. Beyond regulatory evidence generation, the study provides an opportunity to demonstrate clinical workflow utility, support clinician adoption and strengthen the positioning of breast cancer surgery as an initial commercial application for the platforms.



Mayo Clinic head and neck imaging study

The second Mayo Clinic study will assess InVue™ and InForm™ in 35 head and neck cancer patients undergoing tumour resection. Patient recruitment was initiated during the Quarter. The study will generate both in vivo and ex vivo imaging data from a U.S. patient population and evaluate the complementary use of the two devices during and after surgery.

The head and neck program extends evaluation of Optiscan's technology into another complex surgical setting and supports the broader platform opportunity across multiple oncology indications. It also provides further evidence of the versatility of InVue™ and InForm™ across tissue types, procedures and care pathways.

CLINICAL STUDIES PROGRESS

Optiscan's clinical programs continued to advance during the Quarter, generating imaging data and workflow experience that supported the InForm™ and InVue™ submissions and will continue to strengthen the evidence base for regulatory engagement, clinical adoption and commercialisation.

Clinical Site	Device	Tissue	Participants ^{1,2}	Progress % Complete 
The Royal Melbourne Hospital	InVue™ InForm™	Breast	40 / 50	 80%
St John of God Murdoch Hospital	InVue™ InForm™	Head and neck	13 / 50	 26%
Australian Clinical Labs	InForm™	Multiple	84	Ongoing
Mayo Clinic	InVue™ InForm™	Breast	Up to 35	Recruitment open
Mayo Clinic	InVue™ InForm™	Head and neck	Up to 35	Recruitment open
Universitäts Medizin Mainz	Flexible endomicroscope	Gastrointestinal	Up to 50	Initiated

1. Table shows progress as of 30 September 2026.

2. Participants to date, with the final figure expected to number in the hundreds by the end of the ACL Study.

1. Breast Clinical Study - Royal Melbourne Hospital

The Australian breast study utilising both InVue™ and InForm™ continued to progress, with 40 of the 50 planned cases completed as at 30 September 2026. Results from the first 40 patients produced strong images across healthy and cancerous breast tissue, with selected images included in the supporting evidence for the FDA submissions. Additional study phases are planned to capture preliminary data on the potential for real-time margin assessment during breast-conserving surgery to be used in future submissions.

2. Head and Neck Study - St John of God Murdoch Hospital

The Australian head and neck cancer study progressed into its second stage, with three additional patients enrolled during the Quarter and 13 patients completed in total as at 30 September 2026. The additional patients were imaged using both InVue™ and InForm™, with resulting images included in the Company's FDA submissions. Operational efficiency continued to improve, informed by learnings from other studies.

3. Anatomical Pathology Study - Australian Clinical Labs

The anatomical pathology study continued to build momentum, generating 84 datasets as at 30 September 2026 across a broad range of tissue types and pathologies. The program is expanding Optiscan's image databank, supporting evaluation of InForm™ in a live pathology setting and providing data relevant to workflow optimisation, pathologist training, regulatory activities and future commercial deployment.

4. U.S. Based Surgical Studies - Mayo Clinic

During the Quarter, Optiscan signed two Research Agreements with Mayo Clinic in Rochester, Minnesota, covering breast cancer imaging and head and neck cancer imaging studies. Each study will evaluate InVue™ and InForm™ in integrated surgical-pathology workflows and aims to enrol up to 35 U.S. patients. Recruitment has commenced, supported by an expanded on-site clinical team.

5. Gastrointestinal Clinical Study - Universitäts Medizin Mainz

Preparation and site initiation activities progressed for the observational gastrointestinal imaging study at University Medical Centre Mainz. The study is expected to collect data from up to 50 patients undergoing upper and lower gastrointestinal endoscopy procedures and support ongoing development of Optiscan's next-generation flexible endomicroscope under the Cooperative Research Centres Project with Monash University and Capgemini.

SALES PIPELINE AND COMMERCIALISATION EFFORTS

Commercial Development and Go-to-Market Activities

Optiscan continued to progress its commercialisation activities during the Quarter, with a focus on the U.S. launch of InSpecta™ and further development of sales and marketing resources across its device portfolio.

Building on the go-to-market planning completed in the previous quarter, the Company finalised its commercial materials for InSpecta™ and progressed the development of resources for InForm™ and InVue™. This included product positioning, messaging guides, sales presentations, competitor analysis, and supporting sales tools designed to assist with customer engagement and business development activities.

The Company also continued to refine its sales processes and use of HubSpot Customer Relationship Management system to support customer outreach, lead management and sales pipeline tracking.

During the Quarter, the Company initiated a search for a U.S.-based Chief Commercialisation Officer who will take ownership of establishing and expanding the Company's U.S. commercial team and key accounts in anticipation of FDA clearance of its human-use products.

InSpecta™ U.S. Commercial Launch

In July 2026, Optiscan officially launched InSpecta™ at the American Veterinary Medical Association (AVMA) Convention in California, marking the Company's entry into the U.S. veterinary market.

The Company exhibited at the event, providing live product demonstrations and engaging directly with veterinarians, surgeons, practice owners and other industry representatives. The launch provided an opportunity to introduce InSpecta™ at one of the largest veterinary conferences in the world, enabling Optiscan to engage with prospective customers, generate market awareness and establish Optiscan's profile within the veterinary sector.

Following AVMA, Optiscan continued its U.S. marketing and customer engagement activities, by exhibiting InSpecta™ at the Veterinary Cancer Society annual meeting in Minneapolis, Minnesota in late September, and then again subsequent to the Quarter at the American College of Veterinary Surgeons in Charlotte, North Carolina, and the American Association of Veterinary Laboratory Diagnosticians in Madison, Wisconsin in October.

U.S. Business Development

During the Quarter, Optiscan engaged an experienced U.S.-based outsourced business development team to support business development activities, with an initial focus on InSpecta™ following its U.S. launch. The team is supporting the identification and engagement of prospective customers, development of commercial opportunities and progression of the sales pipeline.

The engagement complements the Company's existing commercial activities and provides additional resources to support its U.S. market development.

PUBLIC RELATIONS AND MARKET ENGAGEMENT INITIATIVES

Optiscan continued its public relations, investor communications and media engagement activities throughout the Quarter, supporting awareness of the Company's clinical progress, commercial developments and broader growth strategy.

The Company received coverage across several financial and industry media outlets, including Stockhead, The Australian and Small Caps. This coverage helped communicate key milestones to investors and broader industry audiences, including the launch of InSpecta™ and progress across the Company's clinical programs.

A number of ASX announcements were supported by investor electronic direct mails, LinkedIn posts and media engagement, including updates on the Mayo Clinic breast cancer study, the Australian Clinical Laboratories digital pathology study and the U.S. head and neck cancer study. These activities formed part of the Company's ongoing efforts to keep shareholders and the broader investment community informed of its progress.

Optiscan also progressed a range of corporate communications and stakeholder engagement initiatives, including industry award submissions and preparations for upcoming conferences. These activities support ongoing engagement with shareholders, clinicians, potential customers and the broader investment community as the Company advances through regulatory review and commercialisation.

BUSINESS OPERATIONS – LAYING THE FOUNDATION FOR GROWTH

Ensuring that Optiscan has the necessary capabilities to execute its strategic objectives remains a key focus as the Company advances toward regulatory clearance and commercialisation. During the Quarter, Optiscan strengthened its manufacturing capability through the appointment of two additional precision technicians, supporting production readiness and the planned scaling of its device portfolio. Recruitment for senior management roles is also underway, aligned with the Company's evolving business needs and growth trajectory. During the Quarter, the Company initiated a search for a Chief Operating Officer who

will take responsibility for scaling its manufacturing and production operations and providing additional executive bandwidth as the Company expands.

During the Quarter, the Company's quality systems and regulatory readiness continued to be enhanced, supporting the lodgement of the InForm™ and InVue™ FDA 510(k) submissions. These activities included internal compliance reviews, supplier oversight and ongoing quality and risk-management initiatives, supporting an effective and audit-ready Quality Management System.

Optiscan also continued to strengthen its information technology environment during the Quarter, including upgrades to infrastructure supporting its Australian and U.S. telepathology platforms and further cybersecurity improvements. These initiatives enhance operational resilience and provide a more secure and scalable technology foundation for the Company's expanding clinical, regulatory and commercial activities.

CORPORATE UPDATE AND OUTLOOK

The September 2026 Quarter was a defining period of execution for Optiscan, with major regulatory, clinical and commercial workstreams converging. The Company completed the technical, clinical, quality and submission-readiness activities required for its InForm™ and InVue™ FDA 510(k) applications, which were lodged shortly after Quarter-end. This achievement moves both platforms into formal regulatory review and advances Optiscan materially closer to potential U.S. market entry.

At the same time, the Company expanded the clinical foundation supporting these products. New Research Agreements with Mayo Clinic established U.S. breast and head and neck cancer imaging studies, while Australian studies continued to generate imaging data across breast, head and neck and anatomical pathology applications. These programs provide a connection between regulatory evidence, real-world workflow validation, clinician engagement and the development of future clinical reference sites.

Commercial execution also advanced during the Quarter. InSpecta™ was launched into the U.S. veterinary market, commercial materials and sales processes were strengthened across the portfolio, and additional U.S. business development capability was engaged. These activities are building market knowledge and operational experience that can support the future commercialisation of InVue™ and InForm™, subject to regulatory clearance.

Collectively, execution on Optiscan's overall strategy is materially maturing. Differentiated clinical products have entered formal regulatory review, clinical programs are generating evidence across leading institutions and applications, the Company's quality, regulatory and manufacturing capabilities have strengthened, and commercial infrastructure is being developed in parallel. The next phase will focus on progressing FDA review, responding to any requests for additional information, continuing evidence generation, building clinical reference networks and preparing for disciplined U.S. market entry.

The Company invested \$1.957m in R&D during the Quarter, reflecting the substantial testing, validation and regulatory activities undertaken to support the InForm™ and InVue™ U.S. FDA 510(k) submissions. Total cash outflows from operating activities were \$3.184m, primarily driven by this targeted R&D investment. This expenditure advanced the Company's lead platforms into formal regulatory review and strengthened the foundation for potential U.S. commercialisation.

With these foundations in place, Optiscan believes it is well positioned to convert regulatory progress into commercial opportunity and to advance its objective of establishing real-time, cellular-level imaging across surgery, pathology and veterinary medicine.

Note: All related party payments noted in Section 6 of the accompanying Appendix 4C during the Quarter relate to the payment of executive and non-executive director's fees, salaries and superannuation payments.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

OPTISCAN IMAGING LIMITED

ABN

81 077 771 987

Quarter ended ("current quarter")

30 SEPTEMBER 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	56	56
1.2 Payments for		
(a) research and development	(1,957)	(1,957)
(b) product manufacturing and operating costs	(591)	(591)
(c) advertising and marketing	(52)	(52)
(d) leased assets	-	-
(e) staff costs	(470)	(470)
(f) administration and corporate costs	(203)	(203)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	43	43
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	(10)	(10)
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(3,184)	(3,184)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(5)	(5)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (term deposits > 3 months maturity)	-	-
2.6	Net cash from / (used in) investing activities	(5)	(5)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(30)	(30)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (payments for lease liabilities)	(39)	(39)
3.10	Net cash from / (used in) financing activities	(69)	(69)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	14,353	14,353
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,184)	(3,184)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(5)	(5)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(69)	(69)
4.5	Effect of movement in exchange rates on cash held	(2)	(2)
4.6	Cash and cash equivalents at end of period	11,093	11,093

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,093	6,353
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (short-term deposit)	8,000	8,000
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	11,093	14,353

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(268)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	N/A		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,184)
8.2	Cash and cash equivalents at quarter end (item 4.6)	11,093
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	11,093
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	3.5
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer:	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer:	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer:	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

30 October 2026

Date:

The Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.